Drug Discovery Outsourcing Global Market – Forecast To 2025

Published by IQ4I on 14th September 2017 | Ref: 1005266 | This Report Is In Stock

$7200 | Single User
$9000 | Site License
$12000 | Enterprise License
$7200 | Single User
$9000 | Site License
$12000 | Enterprise License

Introduction

Over the last two decades, the Pharmaceutical industry has seen a radical change. The unprecedented downsizing of the internal discovery of big pharmaceuticals, patent expiration, shift towards biologics have seen a surge in the externalization and outsourcing activities. As the industry is looking for new sources of discovery and innovation with limited resources, there is a growing preference to move towards externalization and willingness to embrace the concept of outsourcing. IQ4I estimates that x – x% of the pharma companies R&D spending goes into drug discovery

Almost all the major Pharmaceutical companies are considering outsourcing as a core strategy to fill their discovery pipelines. Outsourcing companies that have precise capabilities through greater flexibility are the preferred ones. Now – a –days, the big pharma relies more on CRO’s for drug discovery capabilities to stock up their pipelines.

The global pharmaceutical outsourcing market was estimated to be $xx billion in 2016 and out of which xx% is accounted for CRO’s. Among the $xx billion CRO market, xx% accounts for discovery-based service i.e $xx billion in 2016 and xx% accounts for Preclinical service and clinical services.

Biologics are expected to grow faster at a CAGR of XX% during the forecast period 2016-25 compared to the small molecules which is growing at a CAGR of XX%. The growth is attributed to the increase in biologics R&D spending and lesser approval time, on the other hand factors such as tedious discovery process and high cost associated are restraining the biologics growth.

Current discovery outsourcing penetration is estimated to be XX% of the global pharmaceutical and biotech industry but poised to reach XX% by 2025 with a CAGR of X%. The pharmaceutical companies should consider several factors before finalizing a CRO partner like therapeutic area expertise, business model, scientific pool, infrastructure, data security, IP policies and last but not least cost-efficiency. Along with CRO’s expertise on drug discovery, the most important aspect the pharma companies look for in a CRO is a verified track record of successfully working in the discovery program of relevant therapeutic area.

Table of Contents

1 INTRODUCTION

2 MARKET ANALYSIS

2.1 RESEARCH METHODOLOGY

2.2 FORECASTING MODEL

2.3 MARKET DYNAMICS

2.4 MARKET SIZING

2.5 EMERGING TRENDS & STRATEGIES

3 BUSINESS OVERVIEW

3.1 BUSINESS MODELS

3.2 BUSINESS EVOLUTION

3.3 CERTIFICATIONS

3.4 DD INDICATORS

3.5 PHARMA R&D EXP & INTENSITY

4 COMPETITOR ANALYSIS

4.1 THERAPEUTIC AREA MATRIX

4.2 GLOBAL FTE RATES

4.3 REGIONAL REVENUES VS FTE

4.4 KEYPLAYERS (REVENUE PER EMPLOYEE, CUSTOMERS, DEALS & TA PIE CHART, COLLABORATION OUTCOMES)

5 LEADING PLAYERS

5.1 OVERVIEW

5.2 CAPABILITIES

5.3 THERAPEUTIC AREA

5.4 BUSINESS MODELS

5.5 COLLABORATIONS

5.6 ACQUISITIONS

6 MARKETING STRATEGIES

6.1 CONFERENCES

6.2 MATCH MAKING WEBSITES

6.3 VIRTUAL PHARMACEUTICALS

6.4 ONLINE RPFS

6.5 NETWORKING WEBSITES

6.6 CLUSTERS

6.7 OTHER MARKETING STRATEGIES

Additional Details

Publisher

IQ4I

Publisher Information

Reference

1005266 |

Number of Pages

203

Report Format

PDF

This report is published by IQ4I

Download Free Report Summary PDF

Drug Discovery Outsourcing Global Market – Forecast To 2025 [Updated: 14-09-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.